KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology Durham, North Carolina (December 3, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global...
Read More
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization...
Durham, North Carolina (April 15, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and...
Durham, North Carolina (April 1, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing...
Alliance combines strengths of both companies resulting in end-to-end offering for efficient and seamless biopharmaceutical development and cGMP...
Durham, North Carolina (December 5, 2023) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the recent appointment of Maggie...
Offering extends legacy of SUREtechnology Platform™ for more efficient workflows and simplified processes. Durham, North Carolina (September 12,...
Durham, North Carolina (August 10, 2023) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments...
KBI's PUREplatform™ is a game-changing microbial expression offering that redefines biopharmaceutical manufacturing. The platform leverages the...
The recent operational consolidation of KBI Biopharma, Inc. and Selexis SA brings a streamlined approach to support customers in rapidly accelerating...
